• Irfan Cicin, Bulent Erdogan, Emrah Gulsen, Sernaz Uzunoglu, Necdet Sut, Esma Turkmen, Hilmi Kodaz, and Sedat Ustundag.
• Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.
• Eur Radiol. 2014 Jan 1;24(1):184-90.

ObjectivesTo determine the frequency of and possible factors related to contrast-induced nephropathy (CIN) in hospitalised patients with cancer.MethodsNinety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline. Relationships between CIN and possible risk factors were investigated.ResultsCIN was detected in 18/90 (20 %) patients. CIN developed in 25.5 % patients who underwent chemotherapy and in 11 % patients who did not (P = 0.1). CIN more frequently developed in patients who had undergone CT within 45 days after the last chemotherapy (P = 0.005); it was also an independent risk factor (P = 0.017). CIN was significantly more after treatment with bevacizumab/irinotecan (P = 0.021) and in patients with hypertension (P = 0.044).ConclusionsThe incidence of CIN after CT in hospitalised oncological patients was 20 %. CIN developed 4.5-times more frequently in patients with cancer who had undergone recent chemotherapy. Hypertension and the combination of bevacizumab/irinotecan may be additional risk factors for CIN development.Key Points• Contrast-induced nephropathy (CIN) is a concern for oncological patients undergoing CT. • CIN occurs more often when CT is performed <45 days after chemotherapy. • Hypertension and treatment with bevacizumab appear to be additional risk factors.

27 keywords...

hide…